Treace to Report Third Quarter 2021 Financial Results on November 4, 2021

Rhea-AI Summary

Treace Medical Concepts (TMCI) has announced the release date for its financial results for Q3 2021, scheduled for November 4, 2021, after the trading day ends. A conference call will follow at 4:30 p.m. ET to discuss the financials. Treace, which specializes in orthopaedic devices for bunion treatment, features the patented Lapiplasty® 3D Bunion Correction™ system, aimed at addressing the root causes of bunions and improving patient recovery. An archived webcast of the call will be available on their investor relations website.

Positive

• Scheduled financial results announcement for Q3 2021 may indicate transparency and ongoing operations.
• Introduction of Adductoplasty™ Midfoot Correction System could enhance product offerings and potentially increase market share.

Negative

• None.

PONTE VEDRA, Fla., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced that it will release financial results for the third quarter of 2021 after the close of trading on Thursday, November 4, 2021. Company management will host a conference call to discuss financial results beginning at 4:30 p.m. ET.

Investors interested in listening to the conference call may do so by dialing (800) 447-0521 for domestic callers or (847) 413-3238 for international callers, followed by Conference ID: 50243277. A live and archived webcast of the event will be available on the Company’s investors relations website at https://investors.treace.com/.

About Treace Medical Concepts

Treace Medical Concepts is a commercial-stage orthopaedic medical device company with the goal of advancing the standard of care for the surgical management of bunion deformities and related midfoot correction. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction™ system - a combination of instruments, implants, and surgical methods designed to correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Treace recently expanded its offering with the Adductoplasty™ Midfoot Correction System, designed for reproducible correction of the midfoot which could provide further support to hallux valgus patients. For more information, please visit www.treace.com.

Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940

Investors:
Gilmartin Group
Lynn Lewis or Vivian Cervantes
IR@treace.net

FAQ

When will Treace Medical Concepts release its Q3 2021 financial results?

Treace Medical Concepts will release its Q3 2021 financial results on November 4, 2021, after the close of trading.

What time is the Treace Medical Concepts conference call for Q3 2021 results?

The conference call will take place at 4:30 p.m. ET on November 4, 2021.

How can I access the Treace Medical Concepts Q3 2021 results conference call?

You can listen to the conference call by dialing (800) 447-0521 for domestic calls or (847) 413-3238 for international calls, using Conference ID: 50243277. An archived webcast will also be available on their investor relations website.

What new product did Treace Medical Concepts introduce recently?

Treace Medical Concepts recently expanded its offerings with the Adductoplasty™ Midfoot Correction System.